• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Oscar Health Inc.

    4/29/25 12:53:53 PM ET
    $OSCR
    Medical Specialities
    Health Care
    Get the next $OSCR alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Oscar Health, Inc.

    (Name of Issuer)


    Class A Common Stock, $0.00001 par value per share

    (Title of Class of Securities)


    687793109

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    687793109


    1Names of Reporting Persons

    JPMORGAN CHASE & CO.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    13,025,334.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    13,775,322.00
    8Shared Dispositive Power

    28,401.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    13,810,923.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.4 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Oscar Health, Inc.
    (b)Address of issuer's principal executive offices:

    75 Varick Street 5th Floor New York NY 10013
    Item 2. 
    (a)Name of person filing:

    JPMORGAN CHASE & CO.
    (b)Address or principal business office or, if none, residence:

    383 Madison Avenue, New York, NY 10179
    (c)Citizenship:

    DE
    (d)Title of class of securities:

    Class A Common Stock, $0.00001 par value per share
    (e)CUSIP No.:

    687793109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    13810923
    (b)Percent of class:

    6.4  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    13025334

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    13775322

     (iv) Shared power to dispose or to direct the disposition of:

    28401

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    J.P. Morgan Securities LLC; JPMorgan Asset Management (UK) Limited; J.P. MORGAN SE; JPMorgan Chase Bank, National Association; J.P. Morgan Investment Management Inc.
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.


    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    JPMORGAN CHASE & CO.
     
    Signature:Rachel Tsvaygoft
    Name/Title:Vice President
    Date:04/29/2025
    Get the next $OSCR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OSCR

    DatePrice TargetRatingAnalyst
    3/13/2025$20.00 → $16.00Overweight → Equal Weight
    Wells Fargo
    12/10/2024$12.00Underperform
    Jefferies
    11/6/2024$21.00 → $13.50Neutral → Underperform
    BofA Securities
    10/7/2024$23.00Neutral
    UBS
    6/26/2024$25.00Overweight
    Piper Sandler
    5/30/2024$28.00Outperform
    Robert W. Baird
    5/30/2024$25.00 → $21.00Buy → Neutral
    BofA Securities
    3/22/2024$20.00Outperform
    Raymond James
    More analyst ratings

    $OSCR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Oscar Health Inc.

      10-Q - Oscar Health, Inc. (0001568651) (Filer)

      5/7/25 7:11:20 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Oscar Health, Inc. (0001568651) (Filer)

      5/7/25 6:24:47 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • SEC Form SCHEDULE 13G filed by Oscar Health Inc.

      SCHEDULE 13G - Oscar Health, Inc. (0001568651) (Subject)

      4/29/25 12:53:53 PM ET
      $OSCR
      Medical Specialities
      Health Care

    $OSCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Thrive Partners Vii Growth Gp, Llc bought $3,185,681 worth of shares (188,395 units at $16.91) (SEC Form 4)

      4 - Oscar Health, Inc. (0001568651) (Issuer)

      11/22/24 4:33:02 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • Co-Founder and Vice Chairman Kushner Joshua bought $3,185,681 worth of shares (188,395 units at $16.91) (SEC Form 4)

      4 - Oscar Health, Inc. (0001568651) (Issuer)

      11/22/24 4:29:47 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • Director Thrive Partners Vii Growth Gp, Llc bought $5,444,343 worth of shares (344,522 units at $15.80) (SEC Form 4)

      4 - Oscar Health, Inc. (0001568651) (Issuer)

      11/18/24 5:02:12 PM ET
      $OSCR
      Medical Specialities
      Health Care

    $OSCR
    Financials

    Live finance-specific insights

    See more
    • Oscar Health Announces Strong Financial Results for First Quarter 2025 And Reaffirms 2025 Guidance

      Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, announced today its financial results for the first quarter ended March 31, 2025. "Oscar reported strong financial results in the first quarter," said Mark Bertolini, CEO of Oscar Health. "We delivered continued top-line growth and bottom-line performance with significant year-over-year increases in revenue and net income. We continue to expect meaningful margin expansion this year as we deliver superior value to our members and partners." Oscar is reaffirming its full year 2025 outlook across all metrics as provided in its financial results press release dated February 4, 2025. First Qu

      5/7/25 6:00:00 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health, Inc. 2025 First Quarter Earnings Conference Call

      Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, will release its first quarter 2025 financial results before the market opens on Wednesday, May 7, 2025. Management will review these results in a conference call beginning at 8:00 AM (ET). The call-in number and webcast link are as follows: Live Call: 1.855.761.5600 Conference ID: 7768132 Webcast The call will be archived and available on Oscar's investor relations website (ir.hioscar.com) following May 7, 2025 for a period of 90 days. About Oscar Health Oscar Health, Inc. ("Oscar") is a leading healthcare technology company built around a full stack technology platform and a relentless

      4/9/25 8:00:00 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health Announces Fourth Quarter and Full Year 2024 Results; Introduces Full Year 2025 Outlook

      Reports Adjusted EBITDA and Net Income Profitability for the First Time in Company History For the year ended December 31, 2024: Total Revenue of $9.2 billion, a 56.5% increase year-over-year Medical Loss Ratio of 81.7%, a 10 bps increase year-over-year SG&A Expense Ratio of 19.1%, a 520 bps improvement year-over-year Net income attributable to Oscar of $25.4 million, or $0.10 of diluted earnings per share, a $296.2 million improvement year-over-year Adjusted EBITDA of $199.2 million, an improvement of $244.5 million year-over-year Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, today announced its financial results

      2/4/25 4:05:00 PM ET
      $OSCR
      Medical Specialities
      Health Care

    $OSCR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Oscar Health Announces Strong Financial Results for First Quarter 2025 And Reaffirms 2025 Guidance

      Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, announced today its financial results for the first quarter ended March 31, 2025. "Oscar reported strong financial results in the first quarter," said Mark Bertolini, CEO of Oscar Health. "We delivered continued top-line growth and bottom-line performance with significant year-over-year increases in revenue and net income. We continue to expect meaningful margin expansion this year as we deliver superior value to our members and partners." Oscar is reaffirming its full year 2025 outlook across all metrics as provided in its financial results press release dated February 4, 2025. First Qu

      5/7/25 6:00:00 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health, Inc. 2025 First Quarter Earnings Conference Call

      Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, will release its first quarter 2025 financial results before the market opens on Wednesday, May 7, 2025. Management will review these results in a conference call beginning at 8:00 AM (ET). The call-in number and webcast link are as follows: Live Call: 1.855.761.5600 Conference ID: 7768132 Webcast The call will be archived and available on Oscar's investor relations website (ir.hioscar.com) following May 7, 2025 for a period of 90 days. About Oscar Health Oscar Health, Inc. ("Oscar") is a leading healthcare technology company built around a full stack technology platform and a relentless

      4/9/25 8:00:00 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Ataraxis AI to Transform Precision Medicine in Cancer Care with $20.4 Million Series A

      With new backing from AIX Ventures, Peter Thiel, and healthcare and AI pioneers, Ataraxis AI is positioned to rapidly bring its first offering, Ataraxis Breast, to market Ataraxis AI, the leading AI precision medicine company, today announced its $20.4 million Series A financing led by AIX Ventures with participation from Floating Point, Thiel Bio, Founders Fund, Bertelsmann Investments, and existing investors, Giant Ventures and Obvious Ventures. The round also received backing from angel investors and healthcare pioneers, including Mario Schlosser, co-founder and former CEO of Oscar Health (NYSE:OSCR), Ryan Fukushima, COO of Tempus, and others. Leading researchers from OpenAI and DeepMin

      3/5/25 2:13:00 PM ET
      $OSCR
      Medical Specialities
      Health Care

    $OSCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Oscar Health Inc.

      SC 13G/A - Oscar Health, Inc. (0001568651) (Subject)

      11/14/24 4:07:27 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Oscar Health Inc.

      SC 13G - Oscar Health, Inc. (0001568651) (Subject)

      11/14/24 1:28:35 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Oscar Health Inc.

      SC 13D/A - Oscar Health, Inc. (0001568651) (Subject)

      11/13/24 9:24:55 PM ET
      $OSCR
      Medical Specialities
      Health Care

    $OSCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Plouffe David

      4 - Oscar Health, Inc. (0001568651) (Issuer)

      4/14/25 4:17:56 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Gassen William

      4 - Oscar Health, Inc. (0001568651) (Issuer)

      4/14/25 4:17:43 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Boyd Jeffery H

      4 - Oscar Health, Inc. (0001568651) (Issuer)

      4/14/25 4:17:33 PM ET
      $OSCR
      Medical Specialities
      Health Care

    $OSCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oscar Health downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Oscar Health from Overweight to Equal Weight and set a new price target of $16.00 from $20.00 previously

      3/13/25 8:18:37 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Jefferies initiated coverage on Oscar Health with a new price target

      Jefferies initiated coverage of Oscar Health with a rating of Underperform and set a new price target of $12.00

      12/10/24 7:59:30 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health downgraded by BofA Securities with a new price target

      BofA Securities downgraded Oscar Health from Neutral to Underperform and set a new price target of $13.50 from $21.00 previously

      11/6/24 7:54:31 AM ET
      $OSCR
      Medical Specialities
      Health Care

    $OSCR
    Leadership Updates

    Live Leadership Updates

    See more
    • Oscar Health, Inc. Announces Inducement Grants under Section 303A.08 of the NYSE Listed Company Manual

      Oscar Health, Inc. ("Oscar") (NYSE:OSCR), a leading healthcare technology company, announced that on January 22, 2024 the Compensation Committee of Oscar's Board of Directors approved the grant of employment inducement restricted stock unit awards covering an aggregate of 104,586 Class A shares of Oscar's common stock to 11 new non-executive employees of Oscar and its affiliates, to induce them to join Oscar and its affiliates. The awards generally vest quarterly over a one-year period following their vesting commencement date, subject to continued employment. The awards were granted under Oscar's 2022 Employment Inducement Award Plan as employment inducement awards pursuant to the New York

      1/26/24 8:00:00 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health Welcomes Two Healthcare Veterans to its Executive Leadership Team

      Oscar Health, Inc. ("Oscar") (NYSE:OSCR), the first health insurance company built around a full stack technology platform, today announced the appointment of two seasoned healthcare executives to round out its leadership bench and further propel its vision to refactor healthcare. Kerry Sain has joined the company as the Executive Vice President of +Oscar, effective August 14, 2023, and Steven Kelmar will join as Executive Vice President and Chief of Staff to the CEO, effective September 21, 2023. In her role, Sain oversees the go-to-market strategy for the +Oscar business and will work closely with Mario Schlosser, President of Technology and Chief Technology Officer, to continue externa

      9/6/23 8:30:00 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health, Inc. Appoints Dr. Sean Martin, MD as New Chief Medical Officer

      Oscar Health, Inc. ("Oscar") (NYSE:OSCR), the first health insurance company built on a full stack technology platform, today announced that Dr. Sean Martin, MD has been appointed to serve as the company's new Chief Medical Officer, effective immediately. Dr. Martin joined Oscar in 2016 and during his tenure has provided clinical leadership across a number of core clinical functions, including enterprise affordability, medical management, market performance, population health, and behavioral health. In his new role, he will be responsible for implementing Oscar's clinical capabilities and enhancing the quality of care and outcomes for its members. "Dr. Martin is an avid champion of the us

      3/15/23 8:30:00 AM ET
      $OSCR
      Medical Specialities
      Health Care